| Entry |
|
|---|
| Name |
Gefurulimab (USAN);
Gefurulimab (genetical recombination) (JAN) |
|---|
| Formula |
C1230H1878N356O391S8
|
|---|
| Exact mass |
28147.5779
|
|---|
| Mol weight |
28164.76
|
|---|
| Sequence |
EVQLVESGGG LVKPGGSLRL SCAASGRPVS NYAAAWFRQA PGKEREFVSA INWQKTATYA
DSVKGRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCAAVFR VVAPKTQYDY DYWGQGTLVT
VSSGGGGAGG GGAGGGGSEV QLVESGGGLV QPGGSLRLSC AASGRAHSDY AMAWFRQAPG
QEREFVAGIG WSGGDTLYAD SVRGRFTNSR DNSKNTLYLQ MNSLRAEDTA VYYCAARQGQ
YIYSSMRSDS YDYWGQGTLV TVSS
(Disulfide bridge: 22-95, 160-234) |
|---|
| Type |
Peptide |
|---|
| Efficacy |
Anti-complement C5 antibody |
|---|
| Type |
Monoclonal antibody |
|---|
| Comment |
Treatment of diseases caused by complement activation
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04610 | Complement and coagulation cascades |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Peptidase inhibitors
alpha2M family
C5
D12208 Gefurulimab (USAN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
